Related references
Note: Only part of the references are listed.Summary From the First Kidney Cancer Research Summit , September 12-13, 2019: A Focus on Translational Research
Toni K. Choueiri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
Keiichiro Mori et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Ziad Bakouny et al.
NATURE COMMUNICATIONS (2021)
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei et al.
CLINICAL CANCER RESEARCH (2021)
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Petra Ross-Macdonald et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
David A. Braun et al.
NATURE MEDICINE (2020)
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study
Joshua J. McFarlane et al.
CLINICAL GENITOURINARY CANCER (2020)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J. Motzer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
M. Meylan et al.
ANNALS OF ONCOLOGY (2020)
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer et al.
NATURE MEDICINE (2020)
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Robert J. Motzer et al.
CANCER CELL (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer
Young Kwang Chae et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer
Han Chang et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
The mRNA Expression Signature and Prognostic Analysis of Multiple Fatty Acid Metabolic Enzymes in Clear Cell Renal Cell Carcinoma
Zuohui Zhao et al.
JOURNAL OF CANCER (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
Guillermo de Velasco et al.
BRITISH JOURNAL OF CANCER (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Strelka2: fast and accurate calling of germline and somatic variants
Sangtae Kim et al.
NATURE METHODS (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao et al.
SCIENCE (2018)
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
B I Rini et al.
ANNALS OF ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic et al.
LANCET ONCOLOGY (2017)
MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
Sean T. Bailey et al.
NATURE COMMUNICATIONS (2017)
Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma
Julia Bellut et al.
SCIENTIFIC REPORTS (2017)
Gene expression markers of Tumor Infiltrating Leukocytes
Patrick Danaher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
New treatment options for metastatic renal cell carcinoma
Alejo Rodriguez-Vida et al.
ESMO OPEN (2017)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark J. Selby et al.
PLOS ONE (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
Marco Gerlinger et al.
NATURE GENETICS (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
